Core Viewpoint - The company has received a Certificate of Suitability (CEP) for the active pharmaceutical ingredient Betamethasone from the European Directorate for the Quality of Medicines (EDQM), enabling it to sell this product in international markets that recognize the CEP [1] Group 1 - The company’s subsidiary, Shandong Sry Pharmaceutical Co., Ltd., is the entity that received the CEP certificate [1] - The issuance of the CEP certificate signifies that the company can expand its sales of Betamethasone in international markets, enhancing its product line [1] - This development is expected to positively impact the company's market competitiveness in the field of chemical raw materials [1]

Core Viewpoint - The company has received the CEP certificate for Dexamethasone raw material from the European Directorate for the Quality of Medicines (EDQM), which allows it to sell this product in international markets that recognize the CEP certification [1][3]. Group 1: Company Information - The company’s subsidiary, Shandong Sry Pharmaceutical Co., Ltd., received the CEP certificate for Dexamethasone, a synthetic corticosteroid used for various medical treatments [1][2]. - The certificate is valid for five years starting from June 17, 2025, and is identified by the number CEP2024-325-Rev00 [1][2]. Group 2: Product and Market Impact - Dexamethasone is used in treating autoimmune diseases, allergic conditions, and as an adjunct therapy for certain acute infections [1][2]. - The global demand for Dexamethasone raw material was 15 tons in 2022, with only five other companies holding valid CEP certificates for this product [2]. - The acquisition of the CEP certificate is expected to enhance the company's competitiveness in the chemical raw material market and expand its product line [3].